Skip to main content
Erschienen in: Annals of Nuclear Medicine 6/2020

10.04.2020 | Original Article

Standardized thresholds of volume-based PET/CT parameters predicting survival of patients with pancreatic head cancer treated with stereotactic body radiation therapy

verfasst von: Weiwei Su, Shengnan Ren, Xiaofei Zhu, Huojun Zhang, Changjing Zuo

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To explore standardized relative thresholds of volume-based parameters on FDG PET/CT, and define the optimal prognosticator among the relative thresholds for patients with locally advanced pancreatic head cancer (LAPHC) treated by stereotactic body radiation therapy (SBRT).

Methods

Thirty-five patients with LAPHC were enrolled, and all underwent SBRT and baseline FDG PET/CT scan. Maximum standardized uptake value (SUVmax) was measured, and metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated under the relative (30%, 40%, and 50%) thresholds of SUVmax. Survival analysis was performed via univariate and multivariate analyses, and independent prognostic factors were determined by Cox proportional hazard models and corresponding survival curves and scatter diagram were drawn.

Results

The median overall survival (OS) and progression-free survival (PFS) were 13.8 and 9.8 months, respectively. On univariate analysis, MTV(40%) < 5.6 cm3, accumulated dose (AD) ≥ 36 Gy and the absence of pancreatic duct (PD) stents were significantly correlated with both superior OS and PFS, TLG (40%) < 29.9 was related to better OS and biological effective dose (BED10) ≥ 57.6 Gy was related to better PFS (all with p < 0.05). Further, multivariate analysis demonstrated both MTV (40%) and AD were independent prognosticators for OS and PFS, and BED10 was an independent predictor for PFS (all with p < 0.05). Scatter diagram showed BED10 to be a stronger clinical prognosis predictor for PFS than AD.

Conclusions

MTV (40%) was the optimal prognosticator among the relative thresholds of SUVmax for tumor delineation on PET/CT for LAPHC patients receiving SBRT. AD was also favorable indicators for OS and PFS of patients, and BED10 was more sensitive than AD in predicting the PFS of patients.
Literatur
1.
Zurück zum Zitat Tempero MA, Malafa MP, Alhawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRef Tempero MA, Malafa MP, Alhawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRef
2.
Zurück zum Zitat Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRef Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRef
3.
Zurück zum Zitat Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21.CrossRef Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21.CrossRef
4.
Zurück zum Zitat Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.CrossRef Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.CrossRef
5.
Zurück zum Zitat Song MK, Chung JS, Shin HJ, Moon JH, Ahn JS, Lee HS, et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res. 2013;37:58–63.CrossRef Song MK, Chung JS, Shin HJ, Moon JH, Ahn JS, Lee HS, et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res. 2013;37:58–63.CrossRef
6.
Zurück zum Zitat Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420–5.CrossRef Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420–5.CrossRef
7.
Zurück zum Zitat Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, et al. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med. 2013;38:778–83.CrossRef Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, et al. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med. 2013;38:778–83.CrossRef
8.
Zurück zum Zitat Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH, et al. Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy. Yonsei Med J. 2014;55:1498–506.CrossRef Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH, et al. Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy. Yonsei Med J. 2014;55:1498–506.CrossRef
9.
Zurück zum Zitat Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW Jr, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27–322.CrossRef Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW Jr, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27–322.CrossRef
10.
Zurück zum Zitat Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471–7.CrossRef Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471–7.CrossRef
11.
Zurück zum Zitat Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22.CrossRef Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22.CrossRef
12.
Zurück zum Zitat Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, et al. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:539–46.CrossRef Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, et al. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:539–46.CrossRef
13.
Zurück zum Zitat Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628–35.CrossRef Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628–35.CrossRef
14.
Zurück zum Zitat Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 2014;55:1584–90.CrossRef Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 2014;55:1584–90.CrossRef
15.
Zurück zum Zitat Zhang A, Ren S, Yuan Y, Li X, Zhu X, Jiang L, et al. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine. 2019;98:e15064.CrossRef Zhang A, Ren S, Yuan Y, Li X, Zhu X, Jiang L, et al. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine. 2019;98:e15064.CrossRef
17.
Zurück zum Zitat Besson FL, Henry T, Meyer C, Chevance V, Roblot V, et al. Rapid Contour-based Segmentation for 18F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. Radiology. 2018;288:277–84.CrossRef Besson FL, Henry T, Meyer C, Chevance V, Roblot V, et al. Rapid Contour-based Segmentation for 18F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. Radiology. 2018;288:277–84.CrossRef
18.
Zurück zum Zitat Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, et al. Phantom study on radiotherapy planning using PET/CT-delineation of GTV by evaluating SUV. J Radiat Res. 2010;51:157–64.CrossRef Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, et al. Phantom study on radiotherapy planning using PET/CT-delineation of GTV by evaluating SUV. J Radiat Res. 2010;51:157–64.CrossRef
19.
Zurück zum Zitat Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1046–54.CrossRef Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1046–54.CrossRef
20.
Zurück zum Zitat Hara R, Itami J, Kondo T, Aruga T, Uno T, Sasano N, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer. 2006;106:1347–52.CrossRef Hara R, Itami J, Kondo T, Aruga T, Uno T, Sasano N, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer. 2006;106:1347–52.CrossRef
21.
Zurück zum Zitat Takasawa O, Fujita N, Kobayashi G, Noda Y, Ito K, Horaguchi J. Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy. Gastrointest Endosc. 2006;65:7299–303. Takasawa O, Fujita N, Kobayashi G, Noda Y, Ito K, Horaguchi J. Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy. Gastrointest Endosc. 2006;65:7299–303.
22.
Zurück zum Zitat Wu J, Song L, Zhang Y, Zhao DY, Guo B, Liu J. Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer. Tumor Biol. 2014;35:2753–7.CrossRef Wu J, Song L, Zhang Y, Zhao DY, Guo B, Liu J. Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer. Tumor Biol. 2014;35:2753–7.CrossRef
23.
Zurück zum Zitat Wang SL, Cao S, Sun YN, Wu R, Chi F, Tang MY, et al. Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. Abdom Imaging. 2015;40:3117–211.CrossRef Wang SL, Cao S, Sun YN, Wu R, Chi F, Tang MY, et al. Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. Abdom Imaging. 2015;40:3117–211.CrossRef
24.
Zurück zum Zitat Beltrame V, Gruppo M, Merigliano S, Bissoli S, Pasquali C, Sperti C, et al. Preoperative 18-FDG PET predicts survival in resectable pancreatic cancer. Eur J Surg Oncol. 2015;41:9–10.CrossRef Beltrame V, Gruppo M, Merigliano S, Bissoli S, Pasquali C, Sperti C, et al. Preoperative 18-FDG PET predicts survival in resectable pancreatic cancer. Eur J Surg Oncol. 2015;41:9–10.CrossRef
25.
Zurück zum Zitat Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2004;7:953–60.CrossRef Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2004;7:953–60.CrossRef
26.
Zurück zum Zitat Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11:1–9.CrossRef Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11:1–9.CrossRef
Metadaten
Titel
Standardized thresholds of volume-based PET/CT parameters predicting survival of patients with pancreatic head cancer treated with stereotactic body radiation therapy
verfasst von
Weiwei Su
Shengnan Ren
Xiaofei Zhu
Huojun Zhang
Changjing Zuo
Publikationsdatum
10.04.2020
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-020-01454-x

Weitere Artikel der Ausgabe 6/2020

Annals of Nuclear Medicine 6/2020 Zur Ausgabe